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BACKGROUND/PURPOSE: Mycobacterium abscessus is the most resistant and rapidly growing mycobac-
terium and causes a wide range of clinical infectious diseases. The relationship between antimicrobial 
susceptibility and clinical outcome needs to be further evaluated.
METHODS: Forty M. abscessus isolates were obtained from clinical specimens of 40 patients at the 
Taichung Veterans General Hospital from January 2006 to December 2008. Antimicrobial susceptibility testing 
was performed using the broth microdilution method according to the recommendations of the National 
Committee for Clinical Laboratory Standards. The clinical manifestations and outcomes were reviewed 
from medical records.
RESULTS: Twenty-two patients were diagnosed with M. abscessus infection. Cough (86.3%), hemoptysis 
(31.8%) and fever (18.1%) were the most common symptoms. The radiographic findings included reticu-
lonodular opacities (50.0%), consolidation (31.8%) and cavitary lesions (18.1%). The 40 isolates were sus-
ceptible to amikacin (95.0%), cefoxitin (32.5%), ciprofloxacin (10.0%), clarithromycin (92.5%), doxycycline 
(7.5%), imipenem (12.5%), moxifloxacin (22.5%), sulfamethoxazole (7.5%) and tigecycline (100%). The rate 
of treatment failure was 27.3% at the end of the 12th month after the start of treatment, although these 
patients were treated with a combination of clarithromycin and other antimicrobial agents.
CONCLUSION: M. abscessus is naturally susceptible to clarithromycin and amikacin, variably susceptible 
to cefoxitin and imipenem, and resistant to most other antimicrobial drugs. Combination therapy with 
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Introduction
Mycobacterium abscessus belongs to a group of rapidly 
growing mycobacteria, which are Runyon group IV organ-
isms that usually form colonies on solid media within 7 
days.1 M. abscessus is the most resistant mycobacterium of the 
known pathogenic rapidly growing mycobacteria, and causes 
a wide spectrum of clinical diseases, including localized 
soft tissue infections, pulmonary disease and dissemi-
nated infections.2 Soft tissue infection by M. abscessus is 
typically caused by contamination of a wound with in-
fected material, non-sterile surgical procedures, injections, 
implantations of foreign bodies or in connection with 
tympanic tubes. M. abscessus causes over 80% of rapidly 
growing mycobacteria chronic respiratory disease.3 Such 
pulmonary diseases are especially common in patients 
with cystic fibrosis. Various types of systemic immunosup-
pression may also predispose individuals to disseminated 
M. abscessus infections.
Clarithromycin and azithromycin are the only effec-
tive oral antimycobacterial agents for M. abscessus and 
should, preferably, be supplemented with other drugs 
since long-term monotherapy may cause resistance.1 
Amikacin is a major parenteral drug used to treat M. abscessus 
that should also be given in combination with another 
drug.2 Because of the variable susceptibility of M. abscessus 
to cefoxitin, imipenem and ciprofloxacin, antibiotic sus-
ceptibility testing of all clinically significant isolates is 
recommended.4
To our knowledge, M. abscessus infection is a rare disease 
and so case numbers are limited. Two studies have re-
viewed the clinical outcomes of 126 patients and 29 
patients respectively,3,5 and the only other related publica-
tions are case reports. Because it is not a common disease, 
the relationship between the clinical outcome of M. absces-
sus infection and its antimicrobial susceptibility has never 
been evaluated in Taiwan. Hence, we assess the clinical 
manifestations of M. abscessus infections, antimicrobial 
susceptibility and responses to antimicrobial therapy.
Methods
M. abscessus isolates
Forty M. abscessus isolates were obtained from the sputum 
(n = 35), blood (n = 4) and cornea (n = 1) of 40 patients at 
Taichung Veterans General Hospital from January 2006 
to December 2008.
Antimicrobial susceptibility testing
Susceptibility testing was performed using the broth 
microdilution method according to the recommenda-
tions of the National Committee for Clinical Laboratory 
Standards.6 The isolates were grown on blood agar and 
incubated at 30°C in room air. The minimal inhibitory 
concentrations (MIC) were read on the 3rd and 4th days. 
The inocula were prepared from actively growing bacteria 
in 10 mL of cation-adjusted Mueller-Hinton broth. The 
strains were then adjusted with cation-adjusted Mueller-
Hinton broth to a bacterial cell density of 106 colony 
forming units/mL (cfu/mL), and diluted to a final inocu-
lum of approximately 5 × 104 cfu/well. Standard reference 
powders of nine antimicrobial agents including amikacin, 
cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipe-
nem, sulfamethoxazole, moxifloxacin and tigecycline were 
obtained from pharmaceutical companies. Antibiotics were 
serially diluted 2-fold in 50 μL of cation-adjusted Mueller-
Hinton broth. The range of antibiotic concentrations was 
256–0.016 μg/mL. The final reaction volume was 100 μL 
(50 μL of antibiotic solution and 50 μL of bacterial suspen-
sion). The MIC breakpoints indicating susceptibility, mode-
rate susceptibility and resistance were interpreted according 
to the tentative guidelines established by the National 
Committee for Clinical Laboratory Standards and the 
modified values for tigecycline by Petrini.2 Staphylococcus 
aureus ATCC 29213 was used as a quality control strain.
Clinical assessment and definitions
The diagnostic criteria for pulmonary M. abscessus infection 
were those outlined in the recommendations of the 
clarithromycin, amikacin and other active antimicrobial agents may lead to clinical improvement; 
however, the rate of treatment failure is still high.
KEYWORDS: Mycobacterium abscessus, rapidly growing mycobacteria, susceptibility testing
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American Thoracic Society 20074 as follows: (1) clinical 
pulmonary symptoms, nodular or cavitary opacities on 
chest radiograph, or a high resolution computed tomo-
graphy (CT) scan showing multifocal bronchiectasis with 
multiple small nodules coupled with the appropriate ex-
clusion of other diagnoses; and (2) one of the following 
microbiological findings: sputum; ≥ 2 positive cultures 
from different samples or bronchial wash/lavage: ≥ 1 posi-
tive culture or lung biopsy: granulomatous inflamma-
tion/acid-fast bacilli plus positive culture from biopsy, 
sputum or bronchial specimen.
The definition of disseminated M. abscessus infection was 
modified from the definition originally developed for the 
diagnosis of tuberculosis as follows: Isolation of M. abscessus 
from blood or bone marrow, from a liver biopsy specimen, or 
from specimens from two or more noncontiguous sites such 
as respiratory tract, lymph node, ascites, pleural effusion, 
pericardial effusion, joint fluid or cerebral spinal fluid.7
Review of radiographs
For the purpose of analysis, we divided each lung into two 
zones (upper and lower lobes), and each zone was assessed 
separately. The radiographic patterns were classified as re-
ticulonodular opacities, consolidation and cavitary lesions.
Outcome measurement
Outcome measurement was performed at the end of the 
12th month after the start of treatment.4
Clinical outcomes
Clinical outcome measurements were obtained from 
chart review. Clinical cure was defined as the resolution of 
the index infection (disappearance of acute signs and 
symptoms related to the infection, or sufficient improve-
ment such that additional antimicrobial therapy was not 
required). Clinical improvement was defined as improve-
ment of clinical symptoms and radiographic findings. 
Clinical failure was defined as one of the following: per-
sisting symptoms and signs, recurrent infection or death 
related to M. abscessus infection. Indeterminate outcome 
was defined as assessment not possible for any reason.
Microbiological outcomes
Microbiological responses were based on the results of the 
appropriate cultures. Eradication was defined as absence 
of M. abscessus on culture. Persistence was defined as pres-
ence of M. abscessus in a patient with clinical failure. 
Indeterminate outcome was defined as assessment not 
possible for any reason.
Results
The results of antimicrobial susceptibility testing are shown 
in Table 1. The susceptibility rates of the 40 M. abscessus 
isolates to the nine antimicrobial agents were as follows: 
amikacin (95.0%), cefoxitin (32.5%), ciprofloxacin (10.0%), 
clarithromycin (92.5%), doxycycline (7.5%), imipenem 
Table 1. In vitro susceptibilities of 40 clinical isolates of Mycobacterium abscessus to 9 antimicrobial agents
 MIC (μg/mL) 
Antimicrobial agents
 Range MIC50 MIC90 
Susceptibilitya
Amikacin 0.125–64  4 16 38/40 (95.0)
Cefoxitin 16–256  32 32 13/40 (32.5)
Ciprofloxacin 0.064–64  4 16 4/40 (10.0)
Clarithromycin 0.032–8 0.25 2 37/40 (92.5)
Doxycycline 0.125–256  32 128 3/40 (7.5)
Imipenem 1–256  16 128 5/40 (12.5)
Moxifloxacin 0.064–32  8 32 9/40 (22.5)
Sulfamethoxazole 16–256 256 256 3/40 (7.5)
Tigecycline 0.064–2  0.5 2 40/40 (100)
aData presented as number of positive cases/total cases (%). MIC = minimum inhibitory concentration.
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(12.5%), moxifloxacin (22.5%), sulfamethoxazole (7.5%) 
and tigecycline (100%).
Twenty-two patients were diagnosed with M. abscessus 
infection. Eighteen M. abscessus isolates from 18 patients 
were considered as colonization. The clinical manifesta-
tions are shown in Tables 2 and 3. Symptoms included 
cough (86.3%), hemoptysis (31.8%), fever (18.1%), chest 
pain (9.1%), dyspnea (4.5%), body weight loss (4.5%) and 
skin rash (4.5%). Some of the 22 patients had associated 
disorders, including previous episodes of tuberculosis 
(7/22, 31.8%), chronic obstructive pulmonary disease 
(3/22, 13.6%), diabetes mellitus (5/22, 22.7%), and malig-
nancy (3/22, 13.6%). Of the three patients with M. abscessus 
bacteremia that received antimicrobial therapy, one died 
due to recurrent bacteremia 6 months later, and the other 
two patients died from unrelated causes.
The most common radiographic finding was reticu-
lonodular opacities (11 patients, 50.0%), predominantly 
in the right upper lung. Cavitary lesions (4 patients, 
18.1%) were seen in upper the lobes and were predomi-
nant in the right upper lobe. Consolidation (7 patients, 
31.8%) was distributed in right upper and left lower lobes. 
One or both upper lobes were involved in 76% of the pa-
tients. Multi-lobar (involving 3 or more lobes) involve-
ment was seen in 19% of patients, and bilateral lobe 
involvement was seen in 52%. Lymph node enlargement 
was not seen in any of the radiographs.
Table 4 lists the clinical and microbiological outcomes. 
The clinical outcomes at the end of the 12th month after 
the start of treatment were as follows: cure (5 patients, 
22.7%); improvement (3 patients, 13.6%); failure (6 pa-
tients, 27.2%); and indeterminate outcome (8 patients, 
36.3%). The microbiological outcomes at the end of the 
12th month after the start of treatment were as follows: 
eradication (7 patients, 31.8%); persistence (7 patients, 
31.8%); and indeterminate outcome (8 patients, 36.3%).
Discussion
The main clinical symptoms of M. abscessus infection 
in this study included cough, hemoptysis and fever. 
Cough was also the most common symptom, along 
with other frequent symptoms such as low-grade fever, 
hemo ptysis, sputum production and weight loss in previ-
ous studies.1,8 In this study, we found that patients had 
higher rates (40%) of structural lung disease, including 
previous episodes of pulmonary tuberculosis and chronic 
obstructive pulmonary disease. Disorders associated with 






Chest pain 2 (9.1)
Dyspnea 1 (4.5)
Body weight loss 1 (4.5)
Skin rash 1 (4.5)
Table 3. Chest radiograph findings of 22 patients with 
Mycobacterium abscessus infection
Chest radiograph n (%)
Location
 Right upper lobe 5 (22.7)
 Left upper lobe 1 (4.5)
 Right lower lobe 1 (4.5)
 Left lower lobe 3 (13.6)
 Bilateral 11 (50.0)
Pattern
 Reticulonodular opacities 11 (50.0)
 Consolidation 7 (31.8)
 Cavitary lesions 4 (18.1)
Table 4. Clinical and microbiologic outcome of 22 patients 




 Cure 5 (22.7)
 Improvement 3 (13.6)
 Failure 6 (27.2)
 Indeterminate 8 (36.3)
Microbiologic outcome 
 Eradication 7 (31.8)
 Persistence 7 (31.8)
 Indeterminate 8 (36.3)
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M. abscessus infection, such as bronchiectasis and prior my-
cobacterial infection, were also observed in a previous study.4 
Disseminated non-tuberculous Mycobacterial disease is 
rare in non-human immunodeficiency virus-infected hosts 
and is associated with various immunosuppressive condi-
tions (e.g. renal or cardiac transplantation, chronic corti-
costeroid use, and hematologic malignancy).1,7 In this 
study, one patient had a history of acute lympho blastic 
leukemia and five patients had diabetes mellitus.
Characteristics of the radiographic findings included 
reticulonodular opacities, consolidation and cavitary le-
sions. These findings were comparable to those described 
in previous studies.3,9 The high resolution CT scan of one 
patient with M. abscessus pulmonary disease showed dif-
fuse bronchiectasis. In contrast, the most common CT 
findings in a previous study were branching nodular 
opacities and cylindrical bronchiectasis.9 In patients with 
pre-existing pulmonary tuberculosis, the new infiltrate of 
M. abscessus infection generally occurred in the same area 
as the previous disease.8
In this study, the most active antimicrobial agents 
against the 40 M. abscessus isolates were tigecycline (100%), 
amikacin (95.0%) and clarithromycin (92.5%), while 
the others were less active. Surveillance data collected 
by the Multicenter Antimicrobial Resistance in Taiwan 
(SMART program) from January 2002 to December 
200310 showed clarithromycin to be less active (52.7%) 
against 167 M. abscessus isolates, whereas ciprofloxacin 
(35.7%) and imipenem (28.9%) were more active than 
suggested by the present study. The activity of the other 
antimicrobial agents in this study was similar to those 
seen in the SMART program. A Korean study of in vitro 
antimicrobial susceptibility (74 isolates of M. abscessus 
obtained from July 2005 to December 2006) revealed that 
amikacin (99%), cefoxitin (99%) and clarithromycin (91%) 
all had excellent activity against most isolates, and that 
imipenem (55%), moxifloxacin (73%) and ciprofloxacin 
(57%) had moderate activity.11 M. abscessus is naturally sen-
sitive to amikacin and clarithromycin/azithromycin, vari-
ably susceptible to cefoxitin and imipenem,2 and very 
resistant to many other chemotherapeutic agents.1
Of the 10 patients treated with a combination of clari-
thromycin and other antimicrobial agents for a period of 
4–8 months, seven still had a positive culture at the end of 
the 12th month after the start of treatment. Although 
combination therapy with a macrolide (clarithromycin or 
azithromycin) and one or more parenteral agents (amikacin 
plus cefoxitin, imipenem) for 2–4 months usually results 
in clinical and microbiological improvement, no regimens 
based on in vitro susceptibility have been shown to produce 
long-term sputum conversion in patients with M. abscessus 
pulmonary diseases.4 This discrepancy between eradica-
tion rates and antimicrobial susceptibility may be due to 
structural lung disease or immunosuppressive conditions. 
For M. abscessus pulmonary disease, radical surgery may be 
curative when it is possible to perform, but pulmonary 
operations on this patient group are associated with 
significant risks.12
The combination of tigecycline for 2 weeks plus 
clarithromycin for 8 months resulted in both cure and 
eradication in one patient. The new drug tigecycline is 
promising. It has low MIC values (≤ 0.03–1 μg/mL) for 
M. abscessus, but needs further clinical evaluation before a 
definite role in therapy can be established.13,14 M. abscessus 
is partially susceptible (23%) to linezolid in vitro, with an 
MIC ≤ 8 μg/mL, but its long-term use is limited due to its 
hematological and neurological side effects, as well as its 
high price.15,16
In summary, M. abscessus is naturally susceptible to 
clarithromycin and amikacin, variably susceptible to cefox-
itin and imipenem, and resistant to most antimicrobial 
drugs. Susceptibility testing is recommended to guide anti-
microbial therapy for M. abscessus infections. Combination 
therapy with clarithromycin, amikacin and other active 
antimicrobial agents may result in clinical improvement; 
however, the rate of treatment failure is still high. The effect 
of combination treatment remains to be determined.
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